BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//SenzaGen - ECPv6.7.0//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://senzagen.com
X-WR-CALDESC:Events for SenzaGen
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Stockholm
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20230326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20231029T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20241027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20251026T010000
END:STANDARD
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20240310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20241103T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250914
DTEND;VALUE=DATE:20250918
DTSTAMP:20260429T194854
CREATED:20250317T151319Z
LAST-MODIFIED:20250909T111839Z
UID:34391-1757808000-1758153599@senzagen.com
SUMMARY:Eurotox 2025
DESCRIPTION:Eurotox 2025\n Athens\, Greece |  Sep 14-17\nBooth #A24\nAdvancing NAMs for Skin Sensitization Testing\nCome meet us at this year’s Eurotox and take part in our scientific activities\, featuring an industry-hosted session\, poster presentations\, and the latest insights on GARD®. Discover how the method provides high performance\, broad applicability\, and quantitative potency information for skin sensitization testing. \nWant to connect with our scientific team while you’re there? \n \nIndustry-Hosted Session\nRegulatory update: GARD®skin in OECD TG 497\nTime: 12:00-13:00 | Tuesday\, September 16\nVenue: N. Skalkotas Hall\n \nJoin us for an interactive scientific session featuring regulatory updates\, case studies\, and a live Q&A. Key highlights: \n\nRegulatory update: GARD®skin included in OECD TG 497.\nCase studies: UVCBs\, Natural Extracts\, Formulations\, Hydrophobic Substances\, and more.\nScientific collaborations: dōTERRA\, BIC\, and Urgo.\n\nLearn how GARD®skin fits into TG 497 and what this means in practice for your regulatory testing strategy. \nPosters\nSpotlight on Essential oils\, Safe dose levels\, Hypoallergenic claims and more\n🎫 P32-09 #644 | Joint poster with DōTERRA\nComparative analysis of skin sensitization thresholds for essential oils: human\, murine\, and GARDskin Dose-Response \n🎫 P32-12 #731 | Joint poster with BIC Skin Creative\nIn vitro skin sensitization potency assessment using GARDskin Dose-Response: a case study on natural extracts-based skin-binding dyes and dye precursors \n🎫 P32-16 #923 | Joint poster with Urgo\nSupporting industry decision-making and hypoallergenicity claims using an experimental setup combining GARDskin Medical Device and Dose-Response protocols \n🎫 P23-04 #314 | ToxHub poster\nDeriving gender-sensitive Occupational Exposure Limits: Case studies on benperidol and dimethylacetamide \nMore at our booth\nExpert guidance for your regulatory challenges\nMeet ToxHub\, our consultancy unit specializing in toxicological risk assessment and regulatory strategy consulting\, with expertise across medical devices\, pharmaceuticals\, cosmetics and chemicals. \nDiscover how ToxHub can support your needs
URL:https://senzagen.com/event/eurotox-2025/
LOCATION:Athens\, Greece
CATEGORIES:Conference
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2025/03/2025-eurotox-banner.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250831
DTEND;VALUE=DATE:20250905
DTSTAMP:20260429T194854
CREATED:20250303T121220Z
LAST-MODIFIED:20250828T194641Z
UID:34240-1756598400-1757030399@senzagen.com
SUMMARY:WC13
DESCRIPTION:13th World Congress on Alternatives and Animal Use in the Life Sciences\n📍 Rio de Janeiro\, Brazil | 🗓 Aug 31-Sep 4\nAt this year’s conference SenzaGen and Unilever co-chair a scientific symposium\, where Dr Andy Forreryd will present how GARD® can be applied to derive a Point-of-Departure (PoD) for quantitative skin sensitization assessment. \n \nSession #79\nUsing NAMs to derive PoDs for NGRA of skin sensitizers: Towards regulatory implementation\nTime: 9:30-11:00 | Tuesday\, September 2\nVenue: Plenary Room\nTogether with speakers from Unilever\, Research Institute for Fragrance Materials (RIFM)\, and Inotiv\, this joint symposium will cover methodological innovations in New Approach Methodologies (NAMs)\, industry case studies on deriving Points of Departure (PoDs) for fragrances\, and the challenges and opportunities for regulatory acceptance. \n \n💻 Incorporating expert knowledge in the Skin Allergy Risk Assessment (SARA) Model: an integrated approach to testing and assessment (IATA) demonstrated in case studies.\nRenato Ivan de Ávila\, PhD @Unilever \n💻 The GARD®skin Dose-Response model to derive a PoD for quantitative skin sensitization assessment.\nAndy Forreryd\, PhD @SenzaGen \n💻 Predicting PoD and potency categories using New Approach Methods: Practical experience from the fragrance industry.\nIsabella Schember\, PhD @Research Institute for Fragrance Materials (RIFM) \n💻 Integrating NAMs for quantitative skin sensitization potency assessment into regulatory frameworks: experience from the work in OECD TG 497\nEmily Reinke\, PhD\, D.A.B.T @Inotiv \nPoster #167\nGARD®skin for Medical Devices: Pre-validation results for implementation in ISO 10993-10\nThe pre-validation study of GARD®skin Medical Device confirms the method is functional\, reproducible and sufficiently accurate to proceed to the validation study phase\, as defined by the ISO TS11796.
URL:https://senzagen.com/event/wc13/
LOCATION:Rio de Janeiro\, Brazil
CATEGORIES:Conference
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2025/03/WC13-Logo-white-background.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20250703T160000
DTEND;TZID=Europe/Stockholm:20250703T170000
DTSTAMP:20260429T194854
CREATED:20250611T091213Z
LAST-MODIFIED:20250630T113645Z
UID:35113-1751558400-1751562000@senzagen.com
SUMMARY:Webcast: GARDskin included in OECD TG 497
DESCRIPTION:Bringing high performance and extended applicability to Defined Approaches for Skin Sensitization (DASS)\nJoin our webcast to learn more about the inclusion of GARD®skin in OECD TG 497— what it means and how it can support your regulatory testing strategy. \nDefined Approaches for Skin Sensitization (DASS) is a key regulatory guideline for combining validated in vitro methods to support hazard and potency assessment. The GARDskin assay is now part of two Defined Approaches (DAs): \n\nThe “2 out of 3” DA for hazard identification.\nThe Integrated Testing Strategy (ITS) for hazard identification and potency sub-categorization (1A\, 1B\, NC).\n\nWith demonstrated high performance and broad applicability to hydrophobic substances (Log P > 3.5) and other challenging chemical entities\, GARDskin improves the performance and extends the overall applicability of DASS\, helping to fill data gaps in regulatory skin sensitization testing.   \n \nAgenda\n\nIntroduction to skin sensitization testing and GARD technology.\nGARDskin (OECD TG 442E) and its inclusion in OECD TG 497.\nCase studies: Improving performance and extending the applicability of DASS for challenging samples.\nLive Q&A.\n\nSpeakers \n \nAndy Forreryd\, PhD\nScientific Liaison Manager @ SenzaGen \n\nCo-developer of the GARD®skin assay (OECD TG 442E).\nMember of the ISO/TC 194/WG 8 on irritation and sensitization.\nMember of OECD expert group on respiratory sensitization. \n\n \nHenrik Johansson\, PhD\nChief Scientist @ SenzaGen \n\nCo-developer of the GARD®skin assay (OECD TG 442E).\nMember of the ISO/TC 194/WG 8 for Irritation and Sensitization.\nMember of the OECD Expert Group on Defined Approaches on Skin Sensitization.\n\n  \n \nThe webinar will last around 40 minutes\, followed by a live Q&A. If you cannot attend the live event\, register anyway to receive the on-demand recording. \n\n 
URL:https://senzagen.com/event/gardskin-in-oecd-497/
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2024/11/Bild1-cropped.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20250423T160000
DTEND;TZID=Europe/Stockholm:20250423T170000
DTSTAMP:20260429T194854
CREATED:20250312T123507Z
LAST-MODIFIED:20250331T142222Z
UID:34303-1745424000-1745427600@senzagen.com
SUMMARY:Webinar: Scientific highlights from 2025 SOT
DESCRIPTION:Advancing NAMs for Skin Sensitization Testing: Natural Extracts\, Medical Devices and Potency\n\nJoin our upcoming webinar\, where SenzaGen’s expert and guest speakers from dōTERRA and Risk Science Consortium will share insights and case studies on the use of New Approach Methodologies (NAMs) for skin sensitization assessment. \nWe’ll present the latest GARD® data from our research and industry collaborations on Natural Extracts\, UVCBs\, and Essential Oils\, explore new opportunities for potency assessment\, and provide updates on regulatory developments for integrating NAMs into Medical Device testing under ISO 10993-10. \nIf you missed SenzaGen’s poster presentations and scientific session at this year’s SOT in Orlando\, this is your chance to catch up! \nThe webinar will last around 50 minutes\, followed by a live Q&A. If you cannot attend the live event\, make sure to register to get access to the recording. \n \nKey takeaways\n\nNew GARD® data on Natural Extracts and Potency Assessment.\nRegulatory update Medical Devices  (ISO 10993-10).\nUser Cases from Clarins\, dōTERRA\, Unilever and more.\n\n\nSpeakers and Agenda\n \nNew GARD® Data on Natural Extracts\, Medical Devices and Skin Sensitization Potency Assessment\nAndy Forreryd\, PhD\nScientific Liaison Manager @ SenzaGen \n\nExpert in in vitro assay development\, genomics\, and machine learning.\nCo-developer of the GARD®skin assay (OECD TG 442E).\nActive member of the ISO/TC 194/WG 8 on irritation and sensitization and OECD expert group on respiratory sensitization.\n\n  \n \nA Comparative Analysis of Human\, Murine\, and GARD®skin Dose-Response Skin Sensitization Thresholds for Essential Oils\nJoe Dawson\nProduct Safety Manager @ dōTERRA International \n\nManages the product safety team at dōTERRA International.\n10 years of experience working as a research scientist in the natural products and cosmetics industries.\nAreas of expertise include literature review\, risk assessment\, and scientific claim substantiation.\n\n \nThey Promised Us Flying Cars: the Use of NAMs for the Safety Assessment of Medical Devices\nRon Brown\nToxicologist @ Risk Science Consortium (Former FDA Scientist) \n\nToxicologist with 35 years of experience in regulatory toxicology and risk assessment.\nFormer FDA reviewer with 25 years of experiences.\nFounding member and former President of the Medical Device and Combination Products Specialty Section of the Society of Toxicology and former President of the Dose-Response Specialty Section of the Society for Risk Analysis.\n\n  \n \n 
URL:https://senzagen.com/event/webinar-2025sot/
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2025/01/Lime-UNIVERSAL-webinar.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250404
DTEND;VALUE=DATE:20250411
DTSTAMP:20260429T194854
CREATED:20250317T145617Z
LAST-MODIFIED:20250317T150648Z
UID:34382-1743724800-1744329599@senzagen.com
SUMMARY:In-cosmetics Global 2025
DESCRIPTION:Meet us at In-cosmetics global in Amsterdam!  \nDate: April 8-10\, 2025
URL:https://senzagen.com/event/2025in-cosmetics-global/
LOCATION:Amsterdam\, Netherlands
CATEGORIES:Conference
ATTACH;FMTTYPE=image/webp:https://senzagen.com/wp-content/uploads/2025/03/INCOS-Global_370x125_Atlas-logo.png.webp
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250404
DTEND;VALUE=DATE:20250405
DTSTAMP:20260429T194854
CREATED:20250317T134428Z
LAST-MODIFIED:20250317T145119Z
UID:34368-1743724800-1743811199@senzagen.com
SUMMARY:2025 SFT annual meeting
DESCRIPTION:Meet us at Swedish Society of Toxicology (SFT)’s annual meeting in Stockholm! This year the theme is “Breaking boundaries: novel methods and approaches advancing toxicology”. \nDate: April 4\, 2025 \nVenue: Samuelssonssalen\, Karolinska Institutet\, Tomtebodavägen 6\, Solna \nSenzaGen’s presentation: Advancing skin sensitization testing with GARD®: Enhancing human relevance and overcoming regulatory challenges \nSpeaker: Tim Lindberg\, PhD\, In vitro Toxicology Expert\, SenzaGen
URL:https://senzagen.com/event/2025sft/
LOCATION:Stockholm\, Sweden
CATEGORIES:Conference
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2025/03/KI_Samuelssonssalen-1.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250331
DTEND;VALUE=DATE:20250402
DTSTAMP:20260429T194854
CREATED:20250303T115948Z
LAST-MODIFIED:20250317T085841Z
UID:34234-1743379200-1743551999@senzagen.com
SUMMARY:Forum SOFHYT 2025
DESCRIPTION:Meet us at the SOFHYT (French Society of Occupational Hygienists) forum “From Prevention to Action: The Occupational Hygienist at the Heart of Occupational Health Risk Management” in Paris on March 31 and April 1. \nOral presentation | 1 April
URL:https://senzagen.com/event/sofhyt2025/
LOCATION:Paris\, France
CATEGORIES:Conference
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2025/03/Forum-SOFHYT.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250326
DTEND;VALUE=DATE:20250328
DTSTAMP:20260429T194854
CREATED:20250303T114445Z
LAST-MODIFIED:20250317T083038Z
UID:34229-1742947200-1743119999@senzagen.com
SUMMARY:6th Annual BTEL Summit & Exhibition
DESCRIPTION:Meet us at the 6th Annual BTEL Summit & Exhibition in Berlin. \nOral presentation | 26 March \nBuilding confidence in New Approach Methodologies (NAMs) for biological safety testing of Medical Devices: a successful case study on skin sensitization testing using GARD®  \nAndy Forreryd\, PhD\nScientific Liaison Manager\, SenzaGen
URL:https://senzagen.com/event/btel2025/
LOCATION:Berlin\, Germany
CATEGORIES:Conference
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2025/03/2025BTEL-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20250316T080000
DTEND;TZID=Europe/Stockholm:20250320T170000
DTSTAMP:20260429T194854
CREATED:20250207T084353Z
LAST-MODIFIED:20250312T122014Z
UID:34052-1742112000-1742490000@senzagen.com
SUMMARY:2025 SOT Annual Meeting & ToxExpo
DESCRIPTION:Booth #637 \nOrange County Convention Center\,  Orlando\, FL. \nMeet us and discover how the GARD® assays are transforming skin sensitization testing. Learn about their role in filling data gaps for in vitro skin sensitizing hazard and quantitative potency assessment\, providing a high-performing and ethical alternative to animal testing. \nExhibitor-Hosted Session\nAdvancing NAMs for Skin Sensitization Testing: Potency\, Challenging Substances and Medical Devices \nW208B | Tuesday\, 18 Mar | 10:45 am-11:45 am \n \n  \nBring your questions and testing challenges!\n \nJoin us for an interactive session that combines essential regulatory updates\, case studies\, and a live Q&A! Gain exclusive insights on the latest GARD®data from SenzaGen’s research and industry collaborations\, including key advancements in testing challenging substances\, medical devices\, and quantitative potency assessment. We will also share user cases from industry leaders like dōTERRA\, Clarins\, and Bic Skin Creative. \nOur experts will be available to discuss how GARD® innovations can address your needs and advance your work in skin sensitization testing. \nKey Topics \n\nNew GARD® data from industry collaborations on Natural Extracts and Quantitative Potency Assessment.\nRegulatory update WG8 ISO TC194: Medical Devices ISO 10993-10.\nUser Cases from dōTERRA\, Clarins\, Bic Skin Creative\, and more.\n\nSpeakers \n\nRon Brown\, Toxicologist at Risk Science Consortium (former FDA reviewer for Medical Devices)\nJoe Dawson\, Product Safety Manager at doTERRA International\nAndy Forreryd\, Scientific Liaison\, SenzaGen\n\nPosters\n🎫 G367 | Skin Sensitization Potency GHS/CLP Classification \nMarch 17\, 1:45 pm -4:15 pm | #3242 Subcategorization of skin sensitizers into UN GHS categories using GARD®skin Dose-Response \n🎫 D217 | Medical Devices Testing ISO 10993-10 \nMarch 19\, 9:15 am -11:45 am | #4382 Pre-validation Results from GARD®skin for Medical Devices: In Vitro Sensitization Testing of Medical Device Extracts for Implementation in ISO 10993-10 \n🎫 LB352 | NAMs in Occupational Health – Joint poster with Lundbeck \nMarch 20\, 8:30 am -11:30 am | #5251 Assessing skin sensitizing hazard of Drug Products and Active Pharmaceutical Ingredients using GARD®: New Approach Methodology in Occupational Health and Safety \n🎫 F310 |  Application for Pharmaceuticals – Joint poster presented by SafeBridge \nMar 18\, 1:45 pm-4 pm | #3838 Comparison of β-lactam ring containing substances gene expression signatures related to therapeutic mechanism and the Adverse Outcome Pathway (AOP) for sensitization \n 
URL:https://senzagen.com/event/2025sot/
LOCATION:Orlando\, Fl\, United States
CATEGORIES:Conference
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2025/02/2025-SOT.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20250306T160000
DTEND;TZID=Europe/Stockholm:20250306T170000
DTSTAMP:20260429T194854
CREATED:20250219T140200Z
LAST-MODIFIED:20250219T145527Z
UID:34108-1741276800-1741280400@senzagen.com
SUMMARY:Webinar: Regulatory updates & industry perspectives on NAMs for Medical Device Safety
DESCRIPTION:Join us for an insightful webinar on the evolving role of New Approach Methodologies (NAMs) in regulatory biological safety assessments and how they can be used to help develop safe materials in the pre-regulatory space. With shifting standards and increasing adoption of NAMs\, understanding their impact is more critical than ever. \nIn this webinar\, Dr Andy Forreryd\, our expert in in vitro skin sensitization and active member of ISO/TC 194/WG 8\, will break down the latest regulatory updates on ISO 10993-10 and present new data from the GARD®skin Medical Device pre-validation study—a key milestone toward regulatory acceptance. \nYou will also hear from Dr Karla Lienau\, Biological Safety Specialist and Research Engineer at Sonova\, a global leader in Medical Devices\, on how NAMs are shaping product development\, ensuring compliance\, and accelerating innovation. \n \nKey takeaways\n\nRegulatory insights: Understand the latest developments in ISO 10993-10 and the role of in vitro methods.\nGARD® advancements: Learn how this technology supports skin sensitization testing for Medical Devices\, solid materials and extracts in both polar and non-polar vehicles.\nIndustry application: Discover how Sonova integrates NAMs into product development for novel materials.\n\nSpeakers \n \nAndy Forreryd\, PhD\nScientific Liaison @ SenzaGen \n\nExpert in in vitro assay development\, genomics\, and machine learning.\nCo-developer of the GARD®skin assay (OECD TG 442E).\nActive member of the ISO/TC 194/WG 8 on irritation and sensitization and OECD expert group on respiratory sensitization.\n\n\n \nKarla Lienau\, PhD\nBiological Safety Specialist and Research Engineer @ Sonova \n\nResearch engineer specializing in new materials\, coatings\, and technologies for custom hearing aids.\nExpertise in biological safety assessments in compliance with ISO 10993.\nWorks with Class IIa Medical Devices\, ensuring safety and regulatory compliance.\n\n  \n \nThe webinar will last around 50 minutes\, followed by a live Q&A. If you cannot attend the live event\, register now to get access to the recording.
URL:https://senzagen.com/event/webinar-regulatory-updates-nams-for-medical-devices/
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2025/01/Lime-UNIVERSAL-webinar.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20250213T160000
DTEND;TZID=Europe/Stockholm:20250213T170000
DTSTAMP:20260429T194854
CREATED:20250117T160857Z
LAST-MODIFIED:20250207T131544Z
UID:33984-1739462400-1739466000@senzagen.com
SUMMARY:Webinar: Overcoming the challenges of testing Natural Extracts with GARD technology
DESCRIPTION:Join SenzaGen and industry leaders from Clarins and Bic Skin Creative for an in-depth webinar on using GARD® assays for skin sensitization testing.  \nLearn how this innovative technology overcomes the unique challenges of testing complex Natural Extracts\, which often fall outside the scope of traditional methods in OECD 442E Test Guidelines. \nThrough case studies\, we will showcase how GARD® has supported the safety assessment of natural extract-based products\, providing reliable solutions for today’s testing needs. \n \nKey learnings and highlights\n\nChallenges of testing complex natural extracts with conventional methods.\nHow the GARD® technology brings new opportunities to the field of skin sensitization.\nCase studies from Clarins and Bic Skin Creative on applying GARD® for natural extract safety assessments.\n\nAgenda and speakers\n1. Advancing skin sensitization testing with GARD®: Spotlight on Natural Extracts\n \nAndy Forreryd\, PhD\nScientific Liaison @ SenzaGen \nDr Forreryd has many years of experience working with in vitro assay development\, genomics and machine learning\, engaging in collaborations with industry leaders to investigate novel applications for NAM-based sensitization testing\, with the aim to replace the need for animal studies. He is co-developer of the GARDskin assay (OECD TG 442) for the assessment of chemical sensitizers. \n2. Safety assessment of raw materials extracted from plants using GARD®\n \nMylène Landais\nSafety Assessor @ Clarins \nMylène Landais is a toxicology expert currently working for the Clarins Group as an ingredient and formulas safety assessment project manager. She holds a master’s degree in toxicology and\, with 10 years of experience in the cosmetic industry\, mainly works on the safety assessment and risk assessment of finished products and ingredients such as plant extracts and synthetic ingredients. \nThis role is key to ensure the safety of cosmetic products consumers by using alternative to animal testing methods while complying with the main regulations worldwide and facing new challenges\, such as the new Chinese cosmetic regulation. \n3. Assessing skin sensitization potential of new skin-binding dyes using the GARD®skin Dose-Response assay\n \nIan Mallov\nManager of Scientific Research @ Bic Skin Creative \nIan Mallov is manager of scientific research at Bic Skin Creative. Ian grew up in Truro\, Nova Scotia\, Canada and holds a Ph.D. in inorganic chemistry from the University of Toronto. He began as an industrial postdoctoral researcher in the lab of Prof. Chris Caputo at York University with Toronto-based start-up Inkbox Ink. As Inkbox was acquired by Bic\, his role shifted to focus on assessing the efficacy and toxicology of derivatives of natural skin-binding dyes. In his spare time\, he enjoys writing\, running\, and ice hockey. Ian lives in Halifax\, Nova Scotia with his wife and six-month-old daughter. \nWhat are Natural Extracts?\nNatural extracts are are ingredients derived from natural sources like plants and herbs. They are often classified as UVCBs (Unknown or Variable composition\, Complex reaction products\, or Biological materials). These complex substances present unique testing challenges and frequently fall outside the applicability domains of conventional in vitro assays included in OECD Test Guideline for skin sensitization assessment. \n  \n \nThe webinar will last around 50 minutes\, followed by a live Q&A. If you cannot attend the live event\, register now to get access to the recording.
URL:https://senzagen.com/event/webinar-natural-extracts/
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2025/01/Lime-UNIVERSAL-webinar.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20241120T160000
DTEND;TZID=Europe/Stockholm:20241120T170000
DTSTAMP:20260429T194854
CREATED:20241105T080455Z
LAST-MODIFIED:20241105T094128Z
UID:33676-1732118400-1732122000@senzagen.com
SUMMARY:Webinar: In vitro skin sensitization testing: Ensuring conclusive results for challenging samples
DESCRIPTION:Join us for a special re-run of our popular GARD® webinar to explore the recent advancement in Skin Sensitization testing\, focusing on substances that fall outside the applicability domains of the conventional in vitro assays in the OECD Test Guidelines. \nOur skin sensitization experts will address challenges posed by various “Difficult-to-Test” substances\, discussing the applicability domain of key event-based NAMs and existing test strategies. \nYou will learn about the broad applicability of GARD®skin (OECD TG442E) as we review scientific data on challenging substances and exciting projects done in collaboration with industry partners: \nAgrochemical Formulations | Formulated Lubricant Products | Indirectly Acting Haptens | Metals | Natural Extracts | Polymers | UVCBs \nRecorded webinar with live Q&A\nThis recorded webinar will last approximately 45 minutes\, followed by a live Q&A. If you cannot attend the live event\, make sure to register to get access to the recording.  \nKey takeaways\n\nNAMs and test strategies for skin sensitization testing of challenging samples.\nThe applicability domain of GARD®skin for challenging substances and its integration into Defined Approaches.\nCase studies on Agrochemical Formulations\, Formulated Lubricant Products\, Indirectly Acting Haptens\, Metals\, Natural Extracts\, Polymers\, and UVCBs.\n\nWhat are challenging /“difficult-to-test” substances?\nIn the context of skin sensitization testing\, certain groups of chemicals are considered difficult to test using conventional cell-based methods. Examples of commonly recognised “difficult-to-test” samples include indirectly acting haptens\, complex mixtures\, and substances with low water solubility. \nRead more about difficult-to-test substances. \nSpeaker\n \n  \n \n 
URL:https://senzagen.com/event/webinar-spotlight-on-challenging-samples/
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2024/11/BANNER-2.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241028
DTEND;VALUE=DATE:20241031
DTSTAMP:20260429T194854
CREATED:20240905T122507Z
LAST-MODIFIED:20250317T085918Z
UID:33088-1730073600-1730332799@senzagen.com
SUMMARY:ASCCT 13th Annual Meeting
DESCRIPTION:Meet us at the American Society for Cellular and Computational Toxicology (ASCCT) Annual Meeting in Research Triangle Park\, North Carolina. \n  \nOral presentation | Monday\, 28 October | 17:20-17:35\nNAMs for botanical safety evaluation: Case Study on Determine the Safe Use Levels of Genipa Plant Extract in Temporary Tattoo Ink with GARD®\n  \nPoster\nGARD®skin Dose-Response for skin sensitizing potency assessment: Performance on the Reference Chemical Potency List (RCPL)
URL:https://senzagen.com/event/ascct-13th-annual-meeting/
CATEGORIES:Conference
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2024/09/24050-RAD-ASCCT-13th-Annual-Meeting-Graphics-1584x39676_Page_1-scaled-e1725539063290.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20241009T160000
DTEND;TZID=Europe/Stockholm:20241009T170000
DTSTAMP:20260429T194854
CREATED:20240905T141518Z
LAST-MODIFIED:20240924T125128Z
UID:33109-1728489600-1728493200@senzagen.com
SUMMARY:Webinar: Advancing NAMs for Skin Sensitization Testing
DESCRIPTION:Spotlight on Point-of-Departure\, Challenging Substances\, and Active Ingredients\nWe invite you to join our upcoming webinar\, where industry leaders from Lundbeck\, Unilever\, and Cargill\, along with experts from SenzaGen will explain the latest advancements in skin sensitization testing. \nJoin us as we explore the latest data from our GARD® platform on skin sensitization and gain insights from leading industry experts. We will also highlight case studies from collaborative projects\, including those with L’Oréal and ExxonMobil Biomedical Sciences. \nIf you missed SenzaGen’s scientific presentations at Eurotox this year\, this webinar is your chance to catch up on the most recent developments. \nThe webinar will last around 50 minutes\, followed by a live Q&A. If you cannot attend the live event\, make sure to register to get access to the recording. \n \nKey topics\n\nDifficult-to-Test Samples\nUVCBs and Formulated Lubricant Products\nHydrophobic Esters\nDrug products and Active Substances\nPoint-of-Departure for Quantitative Risk Assessment\nDefined Approaches\nIndustry collaborations: Case studies and publications\n\nDon’t miss out on this opportunity to gain valuable insights and network with experts in the field! \nSpeakers\n \n \n \n \n \n 
URL:https://senzagen.com/event/webinar2024eurotoxhighlights/
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2024/09/FINAL-Eurotox-sep-2024-1200x1200px-1-e1727179193578.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20240908T080000
DTEND;TZID=Europe/Stockholm:20240911T170000
DTSTAMP:20260429T194854
CREATED:20240126T092505Z
LAST-MODIFIED:20240905T105818Z
UID:31912-1725782400-1726074000@senzagen.com
SUMMARY:Eurotox 2024
DESCRIPTION:Meet us at Booth #56\nCome meet us at booth #56 and join our presentations to hear the latest news about GARD® and how the assays are used to fill data gaps in skin sensitizing hazard and quantitative potency assessment. Additionally\, meet ToxHub\, a SenzaGen Group company\, and benefit from expert toxicology and regulatory advice. \n  \n \nIndustry-Hosted Session\n“Advancing NAMs for Skin Sensitization” \nGuest speakers from Lundbeck and Unilever\n \nPosters\nSpotlight on Hydrophobic Esters\, PoD\, Defined Approaches\, and more\n🎫 P01-79 #996 | Joint poster with Cargill\nThe applicability of GARD®skin for assessing skin sensitization potential of hydrophobic esters during product development \n🎫 P19-57 #661 | Joint poster with L’Oréal\nImproved Confidence of Quantitative Sensitizing Potency Assessment for Point of Departure Using GARD®skin Dose-Response \n🎫 P19-75 #840 | Joint poster with Sonova\nIntegrating NAMs into early-stage screening of novel materials intended for use in Medical Devices: Case studies on the use of GARD® for in vitro skin sensitization assessment \n🎫 P20-17 #613 | SenzaGen poster\nGARD®skin as a drop-in replacement KE3-method in OECD GD 497 Defined Approaches \n🎫 P23-21 #937 | ToxHub poster\nWorkflow for Occupational Exposure Limit Determination and Banding: Focus on Skin and Respiratory Sensitization using NAMs approaches \n🎫 LP-28 | ToxHub poster\nRisk Assessment Approaches for Nanomaterials in Medical Devices \n 
URL:https://senzagen.com/event/eurotox2024/
CATEGORIES:Conference
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2024/01/Lime-banner-new-v2.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20240627T160000
DTEND;TZID=Europe/Stockholm:20240627T170000
DTSTAMP:20260429T194854
CREATED:20240521T140048Z
LAST-MODIFIED:20240613T062934Z
UID:32293-1719504000-1719507600@senzagen.com
SUMMARY:Webinar: Meta-analysis of GARD® data\, 200+ chemicals
DESCRIPTION:Spotlight on in vitro quantitative assessment of skin sensitizing potency.\nJoin our upcoming webinar to explore the recent advancement in GARD® for quantitative assessment of skin sensitizing potency.  \nThis session will present a meta-analysis of GARD® data covering over 200 chemicals\, including three blinded datasets generated in collaboration with industry partners. \nThese data will demonstrate how GARD® can estimate a Point of Departure (PoD) and be incorporated into downstream strategies for Quantitative Risk Assessment (QRA)\, contributing to the assessment of safe use levels of chemicals. \nYou will learn how the assay can be used to predict LLNA EC3 values\, Human NOELs\, and GHS/CLP classifications (1A or 1B). \nThe webinar will last around 30 minutes\, followed by a live Q&A. If you cannot attend the live event\, make sure to register to get access to the recording. \n \nKey topics\n\nAn introduction to the prediction model\, genomics\, and machine learning technology.\nThe GARD® assay’s performance in predicting PoD for QRA.\nHow the GARD® assay ensures the safe use of ingredients in consumer products.\n\nSpeakers\n \n 
URL:https://senzagen.com/event/webinar-meta-analysis-of-gard-data/
CATEGORIES:Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20240612T080000
DTEND;TZID=Europe/Stockholm:20240614T170000
DTSTAMP:20260429T194854
CREATED:20240126T094148Z
LAST-MODIFIED:20240126T094148Z
UID:31924-1718179200-1718384400@senzagen.com
SUMMARY:ITCASS and ERGECD meeting 2024
DESCRIPTION:Meet us in Liverpool at the the 11th meeting of Immunotoxicology & Chemical Allergy (ITCASS) and the 30th meeting of European Research Group on Experimental Contact Dermatitis (ERGECD).
URL:https://senzagen.com/event/itcass-and-ergecd-meeting-2024/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20240603T080000
DTEND;TZID=Europe/Stockholm:20240606T170000
DTSTAMP:20260429T194854
CREATED:20240126T091543Z
LAST-MODIFIED:20240521T140249Z
UID:31906-1717401600-1717693200@senzagen.com
SUMMARY:ESTIV Congress 2024
DESCRIPTION:Come meet us at booth #22 and join our presentations to hear the latest news about GARD® and how the assays are used to fill data gaps for skin sensitizing hazard and quantitative potency assessment.  \nAdditionally\, meet ToxHub\, a SenzaGen Group company\, and benefit from expert toxicology and regulatory advice. \nPresentations and Posters\nOur team will showcase several posters and presentations. Dive into new scientific data and discover exciting projects done in collaboration with industry partners. \nTuesday 09:00-10:30 | Presentation in Session 2b\nProject in collaboration with L’Oreal. “Improved confidence of quantitative sensitizing potency assessment for PoD using GARD®skin Dose-Response”\n\nThursday 11:30-12:45 | Presentation in Session 9a\n“Regulatory approval of medical devices according to MDR using in vitro data from GARD®skin Medical Device for skin sensitization assessment” \nPoster | Presented by ToxHub\n#334 | “Integrated Risk Assessment and Compliance Strategies for Nanomaterials in Medical Devices”
URL:https://senzagen.com/event/estiv-congress-2024/
CATEGORIES:Conference
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2024/01/ESTIV-banner.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20240529T090000
DTEND;TZID=Europe/Stockholm:20240530T170000
DTSTAMP:20260429T194854
CREATED:20240521T135437Z
LAST-MODIFIED:20240527T133353Z
UID:32280-1716973200-1717088400@senzagen.com
SUMMARY:Cosmetotest
DESCRIPTION:Program\n‘Introduction to GARDskin (OECD TG 442E) for evaluation of skin sensitization hazard with dose-response option for quantitative risk assessment’\nDate: 30/05\nSession 1: Safety: from irritation to sensitization\nPresenter: Andy Forreryd\, SenzaGen \nBooth: #21
URL:https://senzagen.com/event/cosmetotest/
LOCATION:ENS Lyon\, France
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2024/05/LinkedIn-banner-v1-e1716816802689.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20240423T160000
DTEND;TZID=Europe/Stockholm:20240423T170000
DTSTAMP:20260429T194854
CREATED:20240321T085330Z
LAST-MODIFIED:20240325T130110Z
UID:32117-1713888000-1713891600@senzagen.com
SUMMARY:Webinar: Advancing NAMs for Skin Sensitization Testing
DESCRIPTION:Spotlight on Applicability Domain\, Quantitative Potency Assessment and Medical Devices\nIn case you missed SenzaGen’s poster presentations and scientific session at this year’s SOT\, we are pleased to offer you a new opportunity to participate on April 23\, 2024! \nIn this webinar Dr Andy Forreryd\, SenzaGen’s in vitro toxicology expert\, will summarize the latest GARD data from industry collaborations: \nCorteva Agriscience | ExxonMobil Biomedical Sciences | L’Oréal | IFF | RIFM | Inotiv | Johnson Matthey | Sonova | Duearity \nThe webinar will last around 50 minutes\, followed by a live Q&A. If you cannot attend the live event\, make sure to register to get access to the recording.  \nKey topics\n\nAgrochemical Formulations\nUVCBs and Formulated Lubricant Products\nComplex Mixtures\nMetals\nPoD for Quantitative Risk Assessment\nNESILs for Fragrance Materials\nRegulatory Acceptance According to MDR\nEarly-stage screening of materials intended for use in Medical Devices\n\nSpeakers\n \n  \n \n 
URL:https://senzagen.com/event/webinar-advancing-nams-for-skin-sensitization-testing/
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2024/03/Lime_webinar-final.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20240310T080000
DTEND;TZID=Europe/Stockholm:20240314T170000
DTSTAMP:20260429T194854
CREATED:20231115T134814Z
LAST-MODIFIED:20240306T094116Z
UID:31573-1710057600-1710435600@senzagen.com
SUMMARY:2024 SOT Annual Meeting & ToxExpo
DESCRIPTION:Booth #732\nDiscuss your testing needs with us\n  \nExhibitor-Hosted Session\nExpert round table on NAMs and industry trends\nTuesday\, 12 Mar | 9:00 am-10:00 am\n \n \nPosters\nSpotlight on PoD\, NESILs\, product development and CE-marking of Medical Devices\nMonday\, 11 Mar | 9:15 am-11:15 am\n🎫 Joint poster with Sonova\nP487 #3362 | Unveiling skin sensitizing potential: case studies on biocompatible material development utilizing the in vitro GARD®skin Medical Device assay \n🎫 Joint poster with Duearity\nP480 #3355 | Regulatory approval of medical devices according to MDR using in vitro data from GARD®skin Medical Device for skin sensitization assessment \n🎫 Joint poster presented by RIFM\nP318 #3205 | Determining a point of departure for skin sensitization potency and quantitative risk assessment of fragrance ingredients using the GARD®skin Dose-Response assay \nTuesday\, 12 Mar | 2:15 pm-4:15 pm\n🎫 Joint poster with L’Oréal\nP739 #4190 | Improved Confidence of Quantitative Sensitizing Potency Assessment for Point of Departure Using GARD®skin Dose-Response \n🎫 Joint poster presented by IFF\nP762 #4213 | A Next Generation Risk Assessment (NGRA) Framework to conduct Quantitative Risk Assessment (QRA2) to determine safe use levels of fragrance ingredients in cosmetic products \n🎫 Joint poster presented by Inotiv\nP738 #4189 | Testing of Regulatory-Relevant Chemicals for Skin and Respiratory Sensitization Hazard \n\n 
URL:https://senzagen.com/event/sot-annual-meeting-2024-toxexpo/
CATEGORIES:Conference
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2023/11/SOT2024.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20240207T160000
DTEND;TZID=Europe/Stockholm:20240207T170000
DTSTAMP:20260429T194854
CREATED:20240116T102331Z
LAST-MODIFIED:20240116T145019Z
UID:31853-1707321600-1707325200@senzagen.com
SUMMARY:Webinar: Spotlight on Difficult-to-Test samples
DESCRIPTION:Join our upcoming webinar to explore the recent advancement in GARD® for Skin Sensitization assessment\, with a specific focus on substances that fall outside the applicability domains of the conventional in vitro assays in the OECD Test Guidelines. \nOur skin sensitization experts will address challenges posed by various Difficult-to-Test substances\, discussing the applicability domain of key event-based NAMs and existing test strategies. \nYou will learn about the broad applicability of GARD®skin OECD TG442E as we present scientific data on Difficult-to-Test substances and exciting projects done in collaboration with industry partners: \nAgrochemical Formulations | Formulated Lubricant Products | Indirectly Acting Haptens | Metals | Natural Extracts | Polymers | UVCBs  \nThe webinar will last around 50 minutes\, followed by a live Q&A. If you cannot attend the live event\, make sure to register to get access to the recording.  \nKey takeaways\n\nNAMs and test strategies for skin sensitization testing of Difficult-to-Test samples.\nThe applicability domain of GARD®skin for challenging substances and its integration into Defined Approaches.\nCase studies on Agrochemical Formulations\, Formulated Lubricant Products\, Indirectly Acting Haptens\, Metals\, Natural Extracts\, Polymers\, and UVCBs.\n\nWhat are “difficult-to-test” substances?\nIn the context of skin sensitization testing\, certain groups of chemicals are considered difficult to test using conventional cell-based methods. Examples of commonly recognised “difficult-to-test” samples include indirectly acting haptens\, complex mixtures\, and substances with low water solubility. \nRead more about difficult-to-test substances. \nSpeakers\n \n  \n \n 
URL:https://senzagen.com/event/webinar-spotlight-on-difficult-to-test-samples/
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2024/01/banner-website-v5-with-dates-1-e1705416604964.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20231214T160000
DTEND;TZID=Europe/Stockholm:20231214T170000
DTSTAMP:20260429T194854
CREATED:20231114T150216Z
LAST-MODIFIED:20231121T211556Z
UID:31504-1702569600-1702573200@senzagen.com
SUMMARY:Webinar: Safety of acrylate monomers\, metals\, and other materials used in medical device development
DESCRIPTION:Join our upcoming free webinar to explore the effective utilization of in vitro methods for safety assessment of materials during product development of Medical Devices.\nWe will discuss recent advancements in in vitro methods for assessing the endpoints of skin irritation and skin sensitization. Learn how to integrate these assessments into your product development process as a complement to chemical characterization and cytotoxicity testing. \nDiscover how this approach can aid in: \nSelecting the right material | Developing new materials | Optimizing production | Choosing the appropriate sterilization method\n\nKey takeaways\n\n*Gain insights into the key fundamentals of the biological evaluation of medical devices and the availability of in vitro biocompatibility testing. \n*Explore the applicability of the in vitro GARD technology in the assessment of medical devices\, supporting both polar and non-polar extraction vehicles (ISO 10993-12). \n*Examine user cases illustrating the safety assessment of acrylate monomers\, metals\, and various materials utilized in medical device development. Learn how these assessments contribute to material selection and production optimization. \n\nSpeakers\n\n \n 
URL:https://senzagen.com/event/webinar-safety-of-acrylate-monomers-metals-and-other-materials-used-in-medical-device-development/
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2023/11/Webinar-banner-v10-without-date_MD-product-development.png.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231116
DTEND;VALUE=DATE:20231118
DTSTAMP:20260429T194854
CREATED:20230824T072405Z
LAST-MODIFIED:20231108T143625Z
UID:30942-1700092800-1700265599@senzagen.com
SUMMARY:Annual Medical Device Biocompatibility Conference
DESCRIPTION:Presentation \n\nThe GARD®skin Medical Device assay for assessing the skin sensitizing potential of medical devices: A case study on the use of in vitro data in the biological evaluation for CE marking according to MDR\n\nKey Points \n\nA proof-of-concept study using the GARD®skin Medical Device assay to evaluate the skin sensitizing potential of medical device materials according to ISO 10993-10.\nA case study using in vitro data for the endpoints of cytotoxicity\, skin irritation and skin sensitization in the biological evaluation for CE-marking according to MDR to avoid animal testing while accelerating time to market.
URL:https://senzagen.com/event/annual-medical-device-biocompatibility-conference/
LOCATION:Berlin\, Germany
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2023/08/bicompatibility_berlin.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231112
DTEND;VALUE=DATE:20231116
DTSTAMP:20260429T194854
CREATED:20230824T070701Z
LAST-MODIFIED:20231109T141151Z
UID:30935-1699747200-1700092799@senzagen.com
SUMMARY:ACT 2023 Annual Meeting
DESCRIPTION:→ Booth #333\nSpotlight on difficult-to-test samples and in vitro quantitative potency assessment as an alternative to the Local Lymph Node Assay\nCome meet us at booth #333 and join our poster presentation to learn how the GARD assays are used to fill data gaps for skin sensitizing hazard and quantitative potency assessment\, providing a high performing and ethical alternative to animal testing. \n→ Joint poster with Takasago\nQuantitative potency assessment of skin sensitizers when developing novel fragrance ingredients\nPractical application of the GARDskin Dose-Response assay to derive a No Expected Sensitization Induction Level (NESIL) value for confirmatory human patch studies to determine safe use level for novel fragrance ingredients \n→ Hot topic\nIn vitro tests supporting Occupational Health\nOccupational allergic dermatitis and asthma are common workplace diseases. By using the in vitro GARD® assays to test for skin and respiratory sensitizers in combination\, it is possible to identify allergens in the work environment and take preventive action. \nCome by our booth to learn more! \n→ Discuss your toxicological risk assessment needs with us!\nMeet our in vitro experts\, Dr Andy Forreryd and Dr Tim Lindberg
URL:https://senzagen.com/event/act-2023-annual-meeting/
LOCATION:Orlando\, Florida\, United States
CATEGORIES:Conference
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2023/08/banner_ACT2023-scaled.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20231018T160000
DTEND;TZID=Europe/Stockholm:20231018T170000
DTSTAMP:20260429T194854
CREATED:20231002T134126Z
LAST-MODIFIED:20231002T155151Z
UID:31216-1697644800-1697648400@senzagen.com
SUMMARY:Webinar: Latest GARD® innovation and research in in vitro skin and respiratory sensitization
DESCRIPTION:We invite you to participate in our webinar where new cutting edge GARD results will be explained by the experts at SenzaGen and our partners.\nIn case you missed SenzaGen’s Scientific Posters and Oral Presentations at this year’s WC12 in Niagara Falls or Eurotox in Ljubljana\, we are pleased to offer you a new opportunity to participate on Oct 18\, 2023! \nCome and join us to explore the most recent GARD® data on skin sensitization\, presented by Emily N Reinke from Inotiv-RTP\, a project done in collaboration with NIH and Burleson Research Technologies. \nAdditionally\, we will showcase our most recent collaborative projects with industry partners: \nMerck| Johnson Matthey | Corteva Agriscience | ExxonMobil Biomedical Sciences | International Flavors & Fragrances (IFF) | Duearity | Inotiv-RTP \n  \n \n  \nKey topics \n\nDifficult-to-Test Samples\nUVCBs and Formulated Lubricant Products\nAgrochemical Formulations\nComplex Mixtures\nMetals\nQuantitative Potency Assessments\nRegulatory Acceptance According to MDR\nProtein Allergens\n\n  \nSpeakers \n \n  \nRegister here \n\nThe webinar will last around 45 minutes\, followed by a live Q&A. If you cannot attend the live event\, make sure to register to get access to the recording.\n\n 
URL:https://senzagen.com/event/webinar-latest-gard-innovation-and-research-in-in-vitro-skin-and-respiratory-sensitization/
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2023/10/Lime_webinarium_WC12-and-2023-Eurotox-1.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230913
DTEND;VALUE=DATE:20230914
DTSTAMP:20260429T194854
CREATED:20230823T145738Z
LAST-MODIFIED:20230823T145738Z
UID:30926-1694563200-1694649599@senzagen.com
SUMMARY:The Fragrance Science & Advocacy Council (FSAC) In-person Workshop
DESCRIPTION:Dermal Sensitizers: A Workshop on State of the Science and Utilization of New Approach Methodologies for Quantitative Risk Assessment\n 
URL:https://senzagen.com/event/the-fragrance-science-advocacy-council-fsac-in-person-workshop/
LOCATION:Arlington\, Virginia\, United States
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2023/08/FSAC-logo.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20230910T080000
DTEND;TZID=Europe/Stockholm:20230923T170000
DTSTAMP:20260429T194854
CREATED:20230313T144734Z
LAST-MODIFIED:20230831T110511Z
UID:30473-1694332800-1695488400@senzagen.com
SUMMARY:Eurotox 2023
DESCRIPTION:New opportunities for skin sensitization testing with GARD®skin OECD TG 442E\nCome meet us at booth #36 and join our poster presentations to learn how the high performance and broad applicability of the GARDskin assay can be used to fill data gaps during regulatory testing and product development.\nMeet also ToxHub\, our latest addition to the Group\, and benefit from expert Toxicology and Regulatory advice.\nBooth #36\n\nDiscuss your toxicological risk assessment needs with us!\n\n \n \nPosters\n\nSpotlight on Difficult-to-Test\, Quantitative Potency\, Medical Devices and E&L Assessment\n\n→ Joint poster with Exxon Mobil\nP07-02 | Assessing the utility of the Genomic Allergen Rapid Detection (GARD®skin) assay to detect dermal sensitization potential in UVCBs and formulated lubricant products \n→ Joint poster with IFF and RIFM\nP22-43 | The GARD® skin Dose-Response assay for determination of a point-of-departure (PoD) for Next Generation Risk Assessment (NGRA) of skin sensitizers: A case study using isocyclocitral \n→ Joint poster with Duearity\nP22-30 | Regulatory approval of medical devices according to MDR using in vitro data from GARD® skin Medical Device for skin sensitization assessment \n→ ToxHub poster\nLP-38 | Toxicological risk assessment of extractable and leachable compounds: mitigating risks in pharmaceutical applications \nNew\n\nTailored Toxicology Services\n\nAt our booth\, you will also meet our independent consultancy unit Toxhub\, specialized in toxicological risk assessment and regulatory strategy consulting\, with expertise in pharmaceuticals\, chemicals\, medical devices and cosmetics. \nExplore ToxHub’s services \n 
URL:https://senzagen.com/event/eurotox-congress-2023/
LOCATION:Ljubljana\, Slovenia\, Slovenia
CATEGORIES:Conference
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2023/03/Eurotox23v2.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230910
DTEND;VALUE=DATE:20230914
DTSTAMP:20260429T194854
CREATED:20230823T144809Z
LAST-MODIFIED:20230824T070750Z
UID:30921-1694304000-1694649599@senzagen.com
SUMMARY:Occupational Toxicology Roundtable 2023
DESCRIPTION:
URL:https://senzagen.com/event/occupational-toxicology-roundtable-2023/
LOCATION:Cleveland\, Ohio\, United States
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2023/08/OTR2023.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20230831T080000
DTEND;TZID=Europe/Stockholm:20230904T170000
DTSTAMP:20260429T194854
CREATED:20230313T144259Z
LAST-MODIFIED:20230831T105454Z
UID:30467-1693468800-1693846800@senzagen.com
SUMMARY:WC12
DESCRIPTION:12th World Congress on Alternatives and Animal Use in the Life Sciences\nOur team and partners will feature the GARD® assays in several posters and presentations. Join us to explore new scientific data and exciting projects done in collaboration with industry partners.\nSymposia\n\nSpotlight on Medical Devices\, Complex Samples and Dose-Response\n\nWednesday\, Aug 30\, 11:00 – 12:30\, Session S410\n→ In collaboration with Duearity\n#515 Application of the GARD®skin Medical Device assay for regulatory approval of medical devices according to MDR \nThursday\, Aug 31\, 9:00 – 10:30\, Session S459\n→ In collaboration with RIFM and IFF\n#208 In vitro determination of a point of departure for Next Generation Risk Assessment (NGRA) of skin sensitizers: Reproducibility and precision of the GARD®skin Dose-Response assay \nThursday\, Aug 31\, 9:00 – 10:30\, Session S459\n→ Presented by Emily N Reinke\, Inotiv-RTP\, in collaboration with NIH and Burleson Research Technologies\n#90 Evaluating Skin Sensitization Hazard of Diverse Chemicals Using GARD®skin \nPosters\n\nSpotlight on Complex Mixtures\, Metals and Protein Allergens\n\nTuesday\, Aug 29\, 12:30 – 14:00\n→ Joint poster with Corteva Agriscience\nA33 #230 | GARD®: a study to investigate the applicability domain for agrochemical formulations \nWednesday\, Aug 30\, 12:30 – 14:00\n→ Joint poster with Johnson Matthey\nF81 #55 | Expanding the applicability domain of NAMs for skin sensitization testing: a case study using GARD®skin for assessment of metals \nWednesday\, Aug 30\, 12:30 – 14:00\n→ Joint poster with Merck\nF80 #498 | Characterization of respiratory sensitizing properties of the protein Subtilisin\, using GARD®air \nMeet our team\n\nMeet and greet with Andy Forreryd
URL:https://senzagen.com/event/12th-world-congress-on-alternatives-and-animal-use-in-the-life-sciences-wc12/
LOCATION:Niagara Falls\, Canada\, Niagara Falls\, Canada
CATEGORIES:Conference
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2023/03/Number-logo.jpg
END:VEVENT
END:VCALENDAR